Author
Listed:
- Chun-Yu Hsieh
(Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan)
- Ying-Erh Chou
(Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan)
- Chia-Yen Lin
(Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Department of Surgery, Division of Urology, Taichung Veterans General Hospital, Taichung 407, Taiwan)
- Shian-Shiang Wang
(School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Department of Surgery, Division of Urology, Taichung Veterans General Hospital, Taichung 407, Taiwan)
- Ming-Hsien Chien
(Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
Department of Medical Education and Research, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan)
- Chih-Hsin Tang
(Department of Pharmacology, School of Medicine, China Medical University, Taichung 404, Taiwan
Chinese Medicine Research Center, China Medical University, Taichung 404, Taiwan
Department of Biotechnology, College of Health Science, Asia University, Taichung 413, Taiwan)
- Jian-Cheng Lin
(Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan)
- Yu-Ching Wen
(Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei 110, Taiwan
Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan)
- Shun-Fa Yang
(Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan)
Abstract
Prostate cancer is among the most common malignant tumors worldwide. Matrix metalloproteinase (MMP)-11 is involved in extracellular matrix degradation and remodeling and plays an essential role in cancer development and metastasis. This study investigated the association of MMP-11 polymorphisms with the clinicopathological characteristics and biochemical recurrence of prostate cancer. Five single-nucleotide polymorphisms (SNPs) of the MMP-11 were analyzed in 578 patients with prostate cancer through real-time polymerase chain reaction analysis. A prostate-specific antigen level of >10 ng/mL, Gleason grade groups 4 + 5, advanced tumor stage, lymph node metastasis, invasion, and high-risk D’Amico classification were significantly associated with biochemical recurrence in the patients ( p < 0.001). MMP-11 rs131451 “TC + CC” polymorphic variants were associated with advanced clinical stage (T stage; p = 0.007) and high-risk D’Amico classification ( p = 0.015) in patients with biochemical recurrence. These findings demonstrate that MMP-11 polymorphisms were not associated with prostate cancer susceptibility; however, the rs131451 polymorphic variant was associated with late-stage tumors and high-risk D’Amico classification in prostate cancer patients with biochemical recurrence. Thus, the MMP-11 SNP rs131451 may contribute to the tumor development in prostate cancer patients with biochemical recurrence.
Suggested Citation
Chun-Yu Hsieh & Ying-Erh Chou & Chia-Yen Lin & Shian-Shiang Wang & Ming-Hsien Chien & Chih-Hsin Tang & Jian-Cheng Lin & Yu-Ching Wen & Shun-Fa Yang, 2020.
"Impact of Matrix Metalloproteinase-11 Gene Polymorphisms on Biochemical Recurrence and Clinicopathological Characteristics of Prostate Cancer,"
IJERPH, MDPI, vol. 17(22), pages 1-12, November.
Handle:
RePEc:gam:jijerp:v:17:y:2020:i:22:p:8603-:d:447748
Download full text from publisher
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:22:p:8603-:d:447748. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.